Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.
Sanofi Pasteur may find itself in the thick of an antitrust case after a judge ruled that a lawsuit alleging that the company illegally monopolizes the market for meningococcal vaccines in the U.S. can move forward.
Novartis ($NVS) saw a setback on its meningitis vaccine Menveo earlier this month, when the FDA unexpectedly rejected a version designed for use in infants.
Novartis ($NVS) has suffered a setback in its effort to expand the use of Menveo, its quadrivalent meningococcal conjugate vaccine. The FDA has turned down its application to extend the approval to
Novartis ($NVS) hit another snag in its quest to broaden use of the meningococcal vaccine Menveo. The FDA has asked for more information on Menveo use in infants, delaying the company's ability to
Good news for makers of the meningitis vaccine--sort of. A CDC advisory panel recommended a booster shot for teenagers, effectively doubling the number of shots kids would get--and doubling the
The CDC's Advisory Committee on Immunization Practices voted 6-5 Wednesday to add a booster dose of the meningitis vaccine at age 16. Reuters notes that health officials want to address waning
What's the best way to boost sales of a key vaccine? Get it approved for infants, of course. And Novartis is one step closer to doing just that with Menveo, its meningococcal shot. Now approved for
The nonprofit group Citizens for Responsibility and Ethics in Washington has sent a letter to the FTC requesting an antitrust investigation into drugmakers that it alleges have offered significant
Just a few weeks after gaining an approval from the FDA, Novartis says that officials from the European Commission have provided a continental OK for its meningitis vaccine blockbuster Menveo. Menveo